Home > Healthcare > Medical Devices > Diagnostic Devices > hereditary testing market
Get a free sample of Hereditary Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Hereditary Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market is highly competitive, with key players such as Myriad Genetics and Illumina leading the field. Companies compete on factors like test accuracy, turnaround time, and pricing. The market is experiencing consolidation as larger firms acquire specialized genetic testing companies to expand their capabilities. Technological advancements in next-generation sequencing and bioinformatics are crucial for gaining a competitive edge. Additionally, firms are focusing on expanding their geographical presence, particularly in emerging markets where the adoption of genetic testing is growing.
Navigating complex regulatory environments across regions is becoming increasingly important for maintaining market leadership. Furthermore, strategic partnerships with healthcare providers and academic institutions are common tactics to enhance market presence and credibility. As the market continues to evolve, companies that can offer comprehensive, cost-effective testing solutions while adapting to regulatory changes are likely to maintain a strong competitive position in this dynamic industry.
Some of the eminent market participants operating in the hereditary testing industry include:
The hereditary non-cancer testing segment dominated the market with USD 5.5 billion in revenue in 2024 and is expected to grow significantly due to increasing awareness about genetic disorders and the importance of early detection.
The global hereditary testing industry was valued at USD 7.6 billion in 2024 and is estimated to grow at a 7.7% CAGR from 2025 to 2034, driven by advancements in genetic testing technologies.
The U.S. hereditary testing market recorded USD 2.2 billion in revenue in 2024 and is projected to witness substantial growth, driven by the rising prevalence of genetic disorders and hereditary cancers.
According to the Centers for Disease Control and Prevention (CDC), hereditary cancers account for approximately 5-10% of all cancer cases in the U.S.
Key players in the industry include Agilent Technologies, Centogene, CooperSurgical, F. Hoffmann-La Roche, Fulgent Genetics, Illumina, Invitae Corporation, Laboratory Corporation of America Holdings, MedGenome, and Myriad Genetics.